A Post Marketing Surveillance (PMS) study on FabiFlu has been commenced by Glenmark Pharmaceuticals to closely monitor the efficacy and safety of the drug in 1000 patients that are prescribed with the oral antiviral. Further, Glenmark has announced a price reduction of 27% for FabiFlu. The new MRP is Rs 75 per tab from the earlier Rs 103 per tab. The price reduction has been made possible through benefits gained from higher yields and better scale, as both the API and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country.
Despite investing significantly in R&D, clinical trials and the manufacturing of FabiFlu (API and formulations), Glenmark has managed to keep the pricing of FabiFlu lower as compared to its price in other countries. FabiFlu in India was originally launched at INR 103/tab, while, its price as INR is higher in the remaining countries. Most patients exhibiting mild to moderate symptoms can benefit from FabiFlu use. Glenmark has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India. The trial results will be available shortly.
